INVO Biosciences

INVO Fertility is a publicly traded healthcare fertility company focused on expanding access to assisted reproductive care through the operation and acquisition of fertility clinics and the commercialization of its FDA-cleared INVOcell intravaginal culture device. The company historically operated as INVO Bioscience, later merged with NAYA Biosciences in 2024, and then returned in 2025 to a fertility-only strategy under the INVO Fertility name. Its business model combines clinic ownership, fertility services, embryology support, and fertility technology distribution. INVOcell is designed to enable fertilization and early embryo development within the patient’s body as a lower-cost alternative within fertility treatment pathways. The company’s current focus is on building a scaled U.S. fertility care platform centered on clinic expansion, technology-enabled care, and broader access to IVF-related services.